Actinic Keratosis, Bowen's disease/ cutaneous squamous cell carcinoma in situ, Basal Cell Carcinoma
Conditions
Interventions
Bowen's disease/ cutaneous squamous cell carcinoma in situ:None
Actinic Keratosis:None
Basal Cell Carcinoma:None
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Retrospective cohort study: a) Patients who were histopathologically diagnosed with AK, cSCCis/BD, or BCC in our hospital between January 2018 and December 2025 and underwent ALA-PDT treatment; b) Age >= 18 years; c) Possess complete clinical information before PDT treatment, pathological reports, and follow-up records for at least 12 months (including efficacy assessments at 3 months and 12 months after treatment). Prospective cohort study: a) Aged >= 18 years, of either gender; b) Clinically and histopathologically confirmed AK, BD, or BCC; c) After clinical evaluation, the lesion is suitable and the patient voluntarily chooses to accept ALA-PDT as the main treatment regimen after being informed; d) Prior to treatment, agree to undergo all examinations specified in the study, including clinical information collection, dermoscopy, and photodynamic fluorescence diagnosis; e) Able to understand the research content, voluntarily sign a written informed consent form, and follow medical advice to complete a follow-up period of at least 12 months;
Exclusion criteria
Exclusion criteria: Retrospective cohort study: a) Lack of clear pathological diagnosis; b) Subjects who received other treatments (such as topical medications, cryotherapy, surgery, etc.) that may affect the efficacy of PDT within 6 months prior to PDT treatment; c) Missing key clinical or follow-up data; Prospective cohort study: a) Patients with known or suspected porphyria, or those allergic to 5-ALA, its metabolites, or excipients; b) Women who are pregnant, breastfeeding, or planning to become pregnant during the study period; c) Received any other treatment for NMSC or precancerous lesions within 6 months; d) Subjects with severe systemic diseases of the heart, liver, kidney, or mental illnesses, who are deemed unsuitable for enrollment by the researchers; e) Participation in other clinical trials that may interfere with the results of this study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Initial Complete Clearance Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sustained Complete Clearance Rate; | — |
Countries
China
Contacts
Public ContactShu Jun Chen
Huashan Hospital, Fudan University
Outcome results
None listed